YOU ARE EXPLORING
Oncology Biomarkers KRAS / BRAF / PIK3CA
Cancer biomarkers | From findings to interpretation

KRAS / BRAF / PIK3CA

Variant-specific roles of KRAS, BRAF, and PIK3CA in tumor-specific targeted treatment and resistance assessment.

Clinical context

Biomarker definition and clinical relevance

KRAS, BRAF, and PIK3CA participate in major growth and survival signaling pathways. Interpretation is both variant-specific and tumor-specific: an alteration may be actionable in one malignancy, predictive of resistance in another, or have no established therapeutic consequence.

Note for clinicians

Final decisions depend on tumor type, stage, previous therapy, a validated assay result, and current drug indications. This content does not imply availability of a bookable laboratory service.

CLINICAL APPLICATIONS

Clinical applications and result interpretation

01

Metastatic colorectal cancer: RAS and BRAF

KRAS/NRAS testing is needed to identify resistance to specified anti-EGFR antibody approaches. KRAS G12C now has defined combination-treatment indications in eligible CRC populations; BRAF V600E also alters regimen selection.

Assay and specimen: Validated NGS or PCR covering relevant KRAS/NRAS exons and codons and BRAF V600E; report exact variants and allele fractions.

Clinical interpretation: KRAS G12C is not equivalent to every KRAS mutation. Clinical action depends on the particular variant.

02

HR-positive, HER2-negative breast cancer

In advanced or metastatic HR+/HER2− breast cancer, activating PIK3CA mutations can support certain targeted combinations in an indicated endocrine-resistant setting. FDA has approved inavolisib plus palbociclib and fulvestrant for a defined PIK3CA-mutated population.

Assay and specimen: Validated tissue or cfDNA testing covering relevant PIK3CA hotspots and any required companion diagnostic.

Clinical interpretation: Variant identity, sample origin, possible false-negative plasma results, and previous therapy all affect eligibility.

03

Other tumors and limits to extrapolation

BRAF V600E has defined treatment implications in melanoma and selected other malignancies, but other BRAF variants and PIK3CA mutations do not automatically create standard treatment options in all tumors.

Assay and specimen: Determine exact variant and functional class; assess accompanying RAS/MAPK pathway alterations when necessary.

Clinical interpretation: Interpret in context of tumor, stage, treatment line, and available approved treatment.

INTERPRETATION / LIMITATIONS

Limitations and interpretive notes

• In metastatic CRC, expanded RAS wild-type status and tumor sidedness may matter for anti-EGFR treatment selection.

• Non-V600 BRAF variants may have different biology and therapeutic sensitivity.

• Somatic tumor findings do not independently establish hereditary susceptibility.

REFERENCES

Guidelines and references

Discuss a specific molecular scenario

For questions about a clinical scenario, use the support form without including any patient identifiers.

Specialist support form →
WhatsAppCall usGet expert consultation